Here are the latest G-BA decisions from the G-BA meeting held on 2 July on the early benefit assessments of Loqtorzi and Minjuvi.
This meeting also marked the first meeting of new G-BA chair Dr Sonja Optendrenk.
A database of all previous G-BA resolutions is available in my store.
- Loqtorzi (toripalimab):
- Relapsed or metastatic nasopharyngeal carcinoma (NPC), first-line, in combination with cisplatin and gemcitabine – Additional benefit not proven; resolution restricted until 15 January 2027
- Oesophageal squamous cell carcinoma, first-line, in combination with cisplatin and paclitaxel – Additional benefit not proven in both subgroups
- Minjuvi (tafasitamab); new indication: Follicular lymphoma, after ≥ 1 prior therapy, in combination with lenalidomide and rituximab – Orphan drug, Hint of not-quantifiable additional benefit in both subgroups